Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FSHD region gene 1 family member B, pseudogene (FRG1BP), is a genomic region on human chromosome 20 previously also known by the aliases C20orf80, FRG1B, and bA348I14.2[1][4][7]. It is classified as a pseudogene, which is a DNA sequence similar to a known gene but typically nonfunctional due to disabling mutations (such as stop codons or frameshift mutations) that prevent it from producing a protein[6]. There is no evidence that FRG1BP produces a functional transcript or protein in humans, and it is not considered to play a role in disease directly[5][6]. Pseudogenes occasionally may have regulatory roles at the RNA level, but there is no known functional or biomarker data for FRG1BP. Genetic variants reported in FRG1BP are classified as likely benign with no pathogenic associations[5]. Consequently, FRG1BP is not a therapeutic target, is not associated with drug interactions, and poses no known safety concerns in the context of drug discovery or gene therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FSHD region gene 1 family member B, pseudogene (FRG1BP).